KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Liabilities: 2016-2025

Historic Total Liabilities for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $2.8 billion.

  • Moderna's Total Liabilities fell 27.63% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 27.63%. This contributed to the annual value of $3.2 billion for FY2024, which is 29.11% down from last year.
  • Per Moderna's latest filing, its Total Liabilities stood at $2.8 billion for Q3 2025, which was up 7.43% from $2.6 billion recorded in Q2 2025.
  • Over the past 5 years, Moderna's Total Liabilities peaked at $10.8 billion during Q3 2021, and registered a low of $2.6 billion during Q2 2025.
  • Its 3-year average for Total Liabilities is $4.0 billion, with a median of $3.9 billion in 2024.
  • In the last 5 years, Moderna's Total Liabilities surged by 1,975.62% in 2021 and then tumbled by 50.05% in 2023.
  • Quarterly analysis of 5 years shows Moderna's Total Liabilities stood at $10.5 billion in 2021, then crashed by 36.00% to $6.7 billion in 2022, then plummeted by 32.12% to $4.6 billion in 2023, then dropped by 29.11% to $3.2 billion in 2024, then declined by 27.63% to $2.8 billion in 2025.
  • Its Total Liabilities stands at $2.8 billion for Q3 2025, versus $2.6 billion for Q2 2025 and $2.6 billion for Q1 2025.